AMGN

Amgen’s Growth Has Been Better than Expected

Amgen’s (AMGN) expected to grow profits just 1% in 2018. And the way I see it, stock growth could likely correlate with profit growth, and I want more than 1% stock growth.

Amgen Continues to Beat the Street

Amgen (AMGN) continues to beat the street, and could be on its way to its fifth consecutive year of double-digit profit growth. Not bad for a safe stock.

Amgen Sags on Poor REPETHA Results

Amgen (AMGN) is down as clinical trial data for one of its big drugs wasn’t up to expectations. But AMGN still has multiple blockbusters, and a good pipeline.

Chapter R: Hold for the Long Term

The best gains are made by holding stocks over long periods of time. Amgen (AMGN) was a long-term winner as it went from $15 to $80 in ten years.

Amgen Continues to Underpromise and Overdeliver

Amgen (AMGN) management continues to underpromise then overdeliver. Last qtr the company crushed analyst estimates once again, pumping out 21% profit growth vs. estimates of 6%.

The Daddy of Biotechs

Who’s your daddy? In the Biotech space it’s Amgen (AMGN) which will be added to the Conservative Stock Portfolio.